๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO ยท Real-Time Price ยท USD
0.88795
-0.0133 (-1.48%)
Nov 18, 2026, 1:08 PM EST - Market open

Spero Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
41.5666.847.98103.7853.5118.26
Revenue Growth
2.48%39.24%-53.77%93.95%193.10%95.67%
Gross Profit
3.0928.34-48.7852.345.92-46.27
Operating Income
7.037.16-72.4826.79-30.57-87.97
Net Income
-29.518.57-68.5722.81-46.42-89.76
Earnings Per Share
-0.510.15-1.270.43-1.23-2.91
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
107.9340.2752.8976.33109.11146.4
Total Debt
-2.94.35.546.6555.75
Net Cash (Debt)
107.9337.3748.5970.79102.4690.65
Net Cash Growth
138.44%-23.09%-31.36%-30.91%13.02%-23.86%
Net Cash Per Share
1.880.630.901.342.732.93

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
--12.62-23.44-33-7.73-64.35
Capital Expenditures
------
Free Cash Flow
--12.62-23.44-33-7.73-64.35
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
7.43%42.42%-101.67%50.43%11.06%-253.45%
Operating Margin
16.91%10.72%-151.08%25.81%-57.13%-481.87%
Pretax Margin
-70.39%13.22%-142.91%24.48%-86.74%-491.65%
Profit Margin
-71.02%12.83%-142.91%21.98%-86.74%-491.65%
FCF Margin
--18.90%-48.86%-31.79%-14.45%-352.47%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-15.31-3.42--
Forward PE
-4.88----
PS Ratio
1.261.971.170.751.6728.35